Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis - Relapsing
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis. The secondary objective of this study was to evaluate the safety and tolerability of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS.

Detailed description:

Arms:
arm 1: Avonex 30 mcg given subcutaneously, once weekly, for 18 months.

Interventions: intervention 1: BG9418 (interferon beta 1-a)
Intervention descriptions: intervention 1: None

Protocol document: